Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: Results of a study of darunavir/ritonavir 600/100mg administered twice daily

C. D. Zorrilla, R. Wright, Oo Osiyemi, Salih Y Yasin, B. Baugh, K. Brown, B. Coate, P. Verboven, J. Mrus, R. Falcon, Tn Kakuda

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives: Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women. Methods: HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using 14C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis. Results: Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12h (AUC12h) for total darunavir was 17-24% lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86% and 10-14% higher, respectively, during pregnancy vs. postpartum. The antiviral response (<50 HIV-1 RNA copies/mL) was 33% at baseline and increased to 73-90% during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature. Conclusions: Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100mg bid in pregnant women.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalHIV Medicine
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Ritonavir
HIV-1
Pregnant Women
Pharmacokinetics
Pregnancy
Postpartum Period
Darunavir
Mothers
Third Pregnancy Trimester
Second Pregnancy Trimester
CD4 Lymphocyte Count
Tandem Mass Spectrometry
Transaminases
Premature Infants
Antiviral Agents

Keywords

  • Darunavir
  • HIV
  • Pharmacokinetics
  • Pregnancy
  • Ritonavir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1 : Results of a study of darunavir/ritonavir 600/100mg administered twice daily. / Zorrilla, C. D.; Wright, R.; Osiyemi, Oo; Yasin, Salih Y; Baugh, B.; Brown, K.; Coate, B.; Verboven, P.; Mrus, J.; Falcon, R.; Kakuda, Tn.

In: HIV Medicine, Vol. 15, No. 1, 01.01.2014, p. 50-56.

Research output: Contribution to journalArticle

Zorrilla, CD, Wright, R, Osiyemi, O, Yasin, SY, Baugh, B, Brown, K, Coate, B, Verboven, P, Mrus, J, Falcon, R & Kakuda, T 2014, 'Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: Results of a study of darunavir/ritonavir 600/100mg administered twice daily', HIV Medicine, vol. 15, no. 1, pp. 50-56. https://doi.org/10.1111/hiv.12047
Zorrilla, C. D. ; Wright, R. ; Osiyemi, Oo ; Yasin, Salih Y ; Baugh, B. ; Brown, K. ; Coate, B. ; Verboven, P. ; Mrus, J. ; Falcon, R. ; Kakuda, Tn. / Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1 : Results of a study of darunavir/ritonavir 600/100mg administered twice daily. In: HIV Medicine. 2014 ; Vol. 15, No. 1. pp. 50-56.
@article{1b3cef78d9374841b1b9ffe2085855c7,
title = "Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: Results of a study of darunavir/ritonavir 600/100mg administered twice daily",
abstract = "Objectives: Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women. Methods: HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using 14C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis. Results: Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12h (AUC12h) for total darunavir was 17-24{\%} lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86{\%} and 10-14{\%} higher, respectively, during pregnancy vs. postpartum. The antiviral response (<50 HIV-1 RNA copies/mL) was 33{\%} at baseline and increased to 73-90{\%} during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature. Conclusions: Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100mg bid in pregnant women.",
keywords = "Darunavir, HIV, Pharmacokinetics, Pregnancy, Ritonavir",
author = "Zorrilla, {C. D.} and R. Wright and Oo Osiyemi and Yasin, {Salih Y} and B. Baugh and K. Brown and B. Coate and P. Verboven and J. Mrus and R. Falcon and Tn Kakuda",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/hiv.12047",
language = "English",
volume = "15",
pages = "50--56",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1

T2 - Results of a study of darunavir/ritonavir 600/100mg administered twice daily

AU - Zorrilla, C. D.

AU - Wright, R.

AU - Osiyemi, Oo

AU - Yasin, Salih Y

AU - Baugh, B.

AU - Brown, K.

AU - Coate, B.

AU - Verboven, P.

AU - Mrus, J.

AU - Falcon, R.

AU - Kakuda, Tn

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women. Methods: HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using 14C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis. Results: Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12h (AUC12h) for total darunavir was 17-24% lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86% and 10-14% higher, respectively, during pregnancy vs. postpartum. The antiviral response (<50 HIV-1 RNA copies/mL) was 33% at baseline and increased to 73-90% during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature. Conclusions: Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100mg bid in pregnant women.

AB - Objectives: Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women. Methods: HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using 14C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis. Results: Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12h (AUC12h) for total darunavir was 17-24% lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86% and 10-14% higher, respectively, during pregnancy vs. postpartum. The antiviral response (<50 HIV-1 RNA copies/mL) was 33% at baseline and increased to 73-90% during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature. Conclusions: Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100mg bid in pregnant women.

KW - Darunavir

KW - HIV

KW - Pharmacokinetics

KW - Pregnancy

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=84888863487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888863487&partnerID=8YFLogxK

U2 - 10.1111/hiv.12047

DO - 10.1111/hiv.12047

M3 - Article

C2 - 23731450

AN - SCOPUS:84888863487

VL - 15

SP - 50

EP - 56

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 1

ER -